Structure back in oral GLP-1 race with strong Phase IIb data

After Structure Therapeutics was beginning to look like one of obesity’s forgotten companies, Phase IIb data for the company’s oral GLP-1R agonist has the biotech both back in investors’ good graces and looking like a strong challenger to Eli Lilly’s first-in-class orforglipron and a potential takeout candidate.

Structure Therapeutics Inc. (NASDAQ:GPCR) announced on Monday data from two Phase II trials for aleniglipron: the Phase IIb ACCESS trial, which tested once-daily doses of up to 120 mg, and the Phase II ACCESS II trial, which evaluated higher doses of up to 240 mg once-daily. ...